Study Explores Genomics of Race in Prostate Cancer
August 6th 2020Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.
HRD Testing Heralds a New Biomarker, but Questions Linger
August 5th 2020Homologous recombination, one of the major mechanisms of defective DNA repair, has emerged as a bona fide therapeutic target, yet its optimal use as a biomarker for patient selection remains a clouded scientific question.
Ripretinib Approval Advances Recurrent GIST Paradigm
August 3rd 2020Ripretinib has become the first therapy specifically approved for the fourth-line treatment of gastrointestinal stromal tumors, a clinical setting with an unmet medical need because of the poor prognosis of patients with progressive disease.